Skip to content

iCo Therapeutics announces enrolment completion and clinical update on Phase II iDEAL study for the treatment of diabetic macular edema (DME)

iCo Therapeutics Inc (TSX-V: ICO), headquartered in Vancouver, Canada has announced completion of enrolment in the Phase II “iDEAL” study designed to evaluate the efficacy and safety of the company’s iCo-007 nucleic acid antisense treatment of DME. The company additionally announced that the trial has experienced a good safety profile to date and that no drug-related serious adverse events had been reported. Commenting on the milestone, Mr. Andrew Rae, President & CEO of iCo Therapeutics stated that, “the last patient was enrolled and treated on June 17. Our principal investigators were interested in extending the timeline in the interest of enrolling as many patients as possible. We look forward to announcing data from the study’s primary endpoint early in 2014.”